Imugene (ASX: IMU) makes new appointment to clinical development team - Kalkine Media

Highlights

• Imugene has appointed Dr John Byon as SVP Clinical Development.
• Dr Byon, an outstanding fit for IMU, has strong hold in novel therapeutics development for cancer patients.
• Dr Byon has held leadership roles at major biopharmaceutical companies.

Imugene Limited (ASX: IMU) has made new addition to its clinical development team with the appointment of industry veteran Dr John Byon. Dr Byon, joining IMU as Senior Vice President of Clinical Development, has significant experience in developing novel therapeutics for cancer patients. He was part of major biopharmaceutical companies where he led and oversaw clinical development activities.

Rich experiences of Dr Byon

Most recently, he was part of Fate Therapeutics as Vice President of Clinical Development in hematology and then in acute myeloid leukemia. In his role, he supervised the clinical strategy for the hematology portfolio and oversaw the ongoing trials in the same field. He was also engaged in restructuring the clinical development team.

Earlier, Dr Byon was associated with Lyell Immunopharma as Senior Medical Director, Head of Clinical Science. At Lyell, he led clinical strategy development for portfolio assets, represented clinical development in joint collaborations and established the internal clinical science function.

Holding a senior medical director position at Juno Therapeutics, he was instrumental in the clinical development of orvacabtagene autoleucel for refractory/relapsed multiple myeloma and other novel CAR T-cell targets.

Dr Byon worked at Genentech for four years and assumed multiple medical director roles. In this capacity, he managed clinical development activities for Tecentriq® in several hematological malignancies. He also represented the company at international advisory board meetings and conceptualised new clinical trials.

Education of Dr Byon

Dr Byon has two doctorate degrees, one in medicine and the other in philosophy, from Tulane University. He has also contributed to many academic publications in the oncology and hematology space.

IMU shares traded at AU$0.068 apiece at the time of writing on 1 September 2023.